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http://dx.doi.org/10.1016/j.ccr.2013.12.004SUMMARYAntibodies (Abs) that preferentially target oncogenic receptors have been increasingly used for cancer
therapy, but tumors often acquire intrinsic Ab resistance after prolonged and costly treatment. Herein we
armed the Ab with IFNb and observed that it is more potent than the first generation of Ab for controlling
Ab-resistant tumors. This strategy controls Ab resistance by rebridging suppressed innate and adaptive
immunity in the tumor microenvironment. Mechanistically, Ab-IFNb therapy primarily and directly targets
intratumoral dendritic cells, which reactivate CTL by increasing antigen cross-presentation within the tumor
microenvironment. Additionally, blocking PD-L1, which is induced by Ab-IFNb treatment, overcomes
treatment-acquired resistance and completely eradicates established tumors. This study establishes a
next-generation Ab-based immunotherapy that targets and eradicates established Ab-resistant tumors.INTRODUCTION
Antibodies (Abs) targeting oncogenic receptors can directly
inhibit tumor cell growth, providing an effective treatment option
for cancer therapy (Hynes and Lane, 2005; Li et al., 2005). The
major therapeutic effect of such Ab therapies is attributed
to direct cytotoxicity to tumor cells by affecting oncogenic
signal transduction. More recently, however, Fc receptor (FcR)
signaling on immune cells has also been recognized to be impor-
tant for an Ab-mediated antitumor effect in vivo (Clynes et al.,
2000; Musolino et al., 2008). We and others have shown that
Ab-mediated tumor regression also depends on adaptive immu-
nity in Ab-sensitive models (Abe`s et al., 2010; Mortenson et al.,Significance
Ab resistance is a major challenge for Ab-based cancer therap
targeting intrinsic resistance and improving direct killing of tum
microenvironment, these direct killing strategies cannot target
reveal herein that type I IFNs are essential and sufficient to bri
tumor regression. We have designed a next generation of Ab-b
revitalizing innate and adaptive immune cells inside the tumor.
immune therapy that may eventually eradicate Ab-resistant tu2013; Park et al., 2010; Stagg et al., 2011; Yang et al., 2013). In
Ab-sensitive tumor models, immune-activating molecules
released during Ab-dependent cell-mediated cytotoxicity or by
stressed tumor cells can effectively activate antigen-presenting
cells (APCs), enhancing their ability to cross-prime and induce
cytotoxic T lymphocyte (CTL) responses. In recent exciting
clinical trials, Abs have been used to block coinhibitory signals
on T cells, including CTL antigen 4 (CTLA-4), programmed cell
death protein 1 (PD-1), and programmed cell death ligand 1
(PD-L1), and these trials have demonstrated that reversing
T cell suppression is another important way to improve the
therapeutic effects against tumors (Brahmer et al., 2012; Sharma
et al., 2011; Topalian et al., 2012; Weber, 2007). These resultsies. Current strategies to overcome Ab resistance focus on
or cells. Because of the heterogeneity of tumor cells and their
all the tumor cells; eventually, Ab resistance will develop. We
dge innate and adaptive immune responses for Ab-induced
ased biologics (Ab-IFNb fusion) to control Ab resistance by
This study open up several avenues for optimizing targeted
mor cells.
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can be further enhanced by selected immunotherapy.
Both primary and acquired resistance are major challenges for
targeted therapy (Bardelli and Siena, 2010; Cobleigh et al.,
1999). Most studies have focused on the intrinsic resistance of
oncogenic signaling, such as mutations within targeted onco-
genes or in genes related to oncogenic pathways that contribute
to Ab resistance (Bardelli and Siena, 2010; Misale et al., 2012;
Sharma et al., 2007; Wheeler et al., 2008; Yonesaka et al.,
2011). Currently, the primary strategy to overcome Ab resistance
in the host is to develop drugs targeting mutated oncogenes or
oncogenic pathway-related genes inside tumor cells (Bostrom
et al., 2009; Fayad et al., 2013; Hurvitz et al., 2013; Krop et al.,
2012; Yoon et al., 2011). On the basis of increasing intrinsic
resistance after treatment with the first generation of antionco-
genic Abs, we propose a tumor-extrinsic strategy to bypass
intrinsic Ab resistance by reactivating both innate and adaptive
immune cells inside the tumor. To achieve this goal, potent
immune molecules that can elicit antitumor responses need to
be identified.
Recently, an increase in type I interferons (IFNs) was found
to correlate favorably with clinical immune responses against
cancer (Fuertes et al., 2011). Furthermore, type I IFN signaling
is essential to initiating antitumor T cell responses during sponta-
neous tumor rejection or various additional antitumor therapies
(Burnette et al., 2011; Diamond et al., 2011; Fuertes et al.,
2011; Stagg et al., 2011). These data suggest that type I IFNs
are essential to initiating specific T cell responses against tumor
cells. Type I IFNs have also been reported to activate memory
T cells during viral infection (Kohlmeier et al., 2010). Thus far,
however, systemic delivery of type I IFNs has been used
cautiously in the clinic for cancer therapy because of its limited
potency and severe side effects (Trinchieri, 2010). Indeed, the
action of this cytokine is poorly understood, because it may
function as either an immune-activating or immune-suppressing
reagent in different disease models (Gonza´lez-Navajas et al.,
2012; Teijaro et al., 2013; Wilson et al., 2013). Timing, duration,
and dosing of type I IFNs could be critical for determining its func-
tion as an immune-activating or immune-suppressing reagent.
Anti-CD20 coupled with IFNa had a better antitumor effect
than anti-CD20 Ab alone by direct and potent killing of type I
IFNa receptor (IFNAR)-positive lymphoma (Xuan et al., 2010).
The data published by Xuan et al. demonstrate that IFNAR
expression on tumor cells is important for the antitumor effect
in an Ab-sensitive tumor model. However, the role of IFNAR on
host cells has not been well-investigated. In this study, we linked
IFNb to antioncogenic receptor Abs that directly target various
carcinomas to test whether it could overcome Ab resistance.
We aimed to investigate the detailed mechanism of how Ab-
IFNb changes the immune-suppressive tumormicroenvironment
to induce antitumor immune responses and design efficient
strategies to optimize targeted immune therapy.
RESULTS
Type I IFNs Are Required for Effective Tumor Response
to Antibody Therapy In Vivo
Type I IFNs have emerged as potential key danger signals that
initiate antitumor T cell responses during spontaneous tumor38 Cancer Cell 25, 37–48, January 13, 2014 ª2014 Elsevier Inc.rejection or after initiation of various antitumor therapies
(Burnette et al., 2011; Diamond et al., 2011; Fuertes et al.,
2011; Stagg et al., 2011). We hypothesize that antioncogenic
receptor Abs induce type I IFN production in tumor tissues to
bridge innate and adaptive immunity. To test whether the sensi-
tivity of tumors to antioncogenic receptor Abs in our models
correlates with type I IFN levels after treatment, we generated
two different tumor cell lines: Ab-sensitive and Ab-resistant.
TUBO cells derived from Her2/neu-transgenic (Her2/neu-Tg)
mice, in which neu is the dominant signal for cell growth, served
as the anti-neu Ab-sensitive tumor cell line (Rovero et al., 2000).
The epidermal growth factor receptor (EGFR)-transfected B16
cells, in which EGFR is unable to deliver growth signals, served
as the tumor cell line that is completely resistant to anti-EGFR
treatment. We treated mice bearing these tumors with their
respective Abs and evaluated type I IFN production inside the
tumor. We found that IFNa5 (Figure 1A) and IFNb (data not
shown) production increased in the Ab-sensitive tumor model,
but not in the Ab-resistant tumor model, suggesting that
increased type I IFN production was caused by Ab-induced
oncogenic receptor blockade and stress. Also, consistent with
these results, we treated EGFR-transfected TUBO cells with
anti-EGFR, in which the transfected EGFR can deliver signals
and partially contribute to cell growth. The EGFR-transfected
TUBO cells served as the tumor cell line that is partially resistant
to anti-EGFR Ab treatment, and we observed a similar reduction
of type I IFN production (Figure S1 available online). To test
whether type I IFNs are required for the Ab-mediated antitumor
effect in vivo, we treated mice with anti-IFNAR-blocking Ab
during anti-neu treatment in the Ab-sensitive TUBO tumor
model. We found that intratumorally blocking type I IFN signaling
impaired the therapeutic effect of anti-neu Ab (Figure 1B), sug-
gesting that type I IFNs might be the cytokines essential for
Ab-mediated tumor regression. It also raises the possibility
that lower levels of type I IFNs may limit immune responses
in host bearing Ab-resistant tumors. To further test whether
delivering additional type I IFNs directly into tumors is sufficient
to control Ab-resistant tumor growth, tumor-bearing mice were
treated with adenovirus encoding IFNb (adenovirus IFNb). As
shown in Figure 1C, adenovirus-IFNb treatment by itself was
able to sufficiently control Ab-resistant tumor growth. Taken
together, these data argue that directing type I IFNs into tumors
may be sufficient to overcome tumor immune evasion or anti-
body resistance.
Targeted Delivery of IFNb Enhances the Antibody-
Mediated Therapeutic Effect
Our data suggest that targeting tumors with type I IFNs has a
potentially therapeutic effect, even for Ab-resistant tumors.
There are two issues to consider when using type I IFNs directly
for cancer therapy: (1) Local delivery of type I IFNs might not be
feasible for many patients, and (2) in the clinic, systemic type I
IFN administration has dose-dependent side effects, and its
limited ability to shrink tumors may be associated with failure
to achieve a high-enough concentration within tumor tissues.
To better increase type I IFN concentrations selectively inside
tumors, we generated an anti-EGFR-IFNb Ab fusion protein
to deliver IFNb directly into EGFR-expressing tumor tissues
(Figure S2A). We first checked that the functions of both
AB C
Figure 1. Type I IFNs Are Induced and
Necessary during Ab-Mediated Tumor
Regression
(A) Wild-Type (WT) BALB/c mice (n = 4/group)
were injected subcutaneously with 5 3 105 TUBO
cells, then 100 mg of anti-neu antibody (Ab) (left
graph) or control immunoglobulin G (IgG) was
administered on day 14. WT B6 mice (n = 4/group)
were injected subcutaneously with 7 3 105 B16-
EGFR cells, then 100 mg of anti-epidermal growth
factor receptor (anti-EGFR) (right graph) or control
IgG was administered on day 14. Four days after
the treatment, the tumor was digested and cells
were sorted into CD45+ and CD45 populations.
Quantitative real-time PCR was performed to
detect the expression of mRNA levels of mouse
interferon a5. Mean ± SD values are shown.
*p < 0.05. Error bars indicate SD.
(B) WT BALB/c mice (n = 5/group) were injected
subcutaneously with 5 3 105 TUBO-EGFR cells,
then 100 mg of anti-neu was administered on
days 14 and 21. Anti-type I interferon-a receptor
(anti-IFNAR) or control immunoglobulin (Ig)
(200 mg of each) was intratumorally administered
on the same days. The growth of the tumor was
measured and compared twice weekly. Mean ±
SEM values are shown. p < 0.05. Error bars indi-
cate SEM.
(C) WT B6 mice (n = 5/group) were injected subcutaneously with 5 3 105 B16-EGFR cells, then 2 3 109 adenovirus-interferon b (adenovirus-IFNb) or control
virus was intratumorally administrated on days 14 and 21. The growth of the tumor was measured and compared twice weekly. Mean ± SEM values are shown.
*p < 0.05 compared with control group. Error bars indicate SEM. One representative experiment of a total of three is depicted.
See also Figure S1.
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Both functions were well-maintained in this fusion protein, as
evidenced by the protein’s ability to bind to EGFR+ cells (Fig-
ure S2B) and activate the IFNAR signaling pathway (data not
shown). We then examined whether anti-EGFR-IFNb could
specifically deliver IFNb to the EGFR+ tumor site in vivo. Indeed,
the concentration of anti-EGFR-IFNb in tumor tissues remained
high for at least 7 days (Figure S2C), whereas it dramatically
decreased in other tissues less than 1 week after initial injection.
Furthermore, we investigated the side effects of the anti-EGFR-
IFNb by measuring serum cytokines, alanine aminotransferase
(ALT), and aspartate aminotransferase (AST) levels (biomarkers
for tissue injury). Among the cytokines we checked, including
tumor necrosis factor, interleukin-12 (IL-12), IFNg, monocyte
chemoattractant protein-1 (MCP-1), IL-6, and IL-10, we
observed slightly increased levels of IFNg and MCP-1 expres-
sion at 6 hr and 1 day after injection (Figure S2D). We observed
no increase in ALT and AST levels above baseline after treatment
(data not shown).
We treated mice bearing established EGFR+ tumors with our
next-generation anti EGFR-IFNb fusion protein or the first-gener-
ation anti-EGFR Ab, cetuximab, in order to compare the potency
of the fusion protein against its predecessor. Impressively, we
observed that the therapeutic effect of anti-EGFR-IFNb was
much more effective than anti-EGFR Ab alone at lower doses
and shorter durations in the partially resistant TUBO-EGFR
tumor model (Figure 2A). Similarly, elevated antitumor effects
were observed in an intramammary fat pad tumor injection
model (data not shown). To further test whether Ab-IFNb could
control tumor growth in a completely resistant tumor model,we tested the efficacy of anti-EGFR-IFNb in B16-EGFR, an
Ab-resistant model. As predicted, though anti-EGFR treatment
alone did not inhibit B16-EGFR tumor growth in vivo, anti-
EGFR-IFNb treatment was again able to greatly control tumor
growth (Figure 2B). KRAS mutations have been reported to be
key factors contributing to anti-EGFR resistance in many
patients bearing EGFR+ tumors (Misale et al., 2012). To test
whether anti-EGFR-IFNb is effective in a KRAS mutation-
induced, Ab-resistant tumor model, we treated a KRAS-mutated
H460 human tumor with anti-EGFR-IFNb in our previously estab-
lished adaptive immune-reconstituted Rag1/ mice (Lee et al.,
2009; Yang et al., 2013). We adoptively transferred 2 million
unpurified lymph node (LN) cells from ovalbumin-specific class
I-restricted T cell (OT-I)-Tg mice, which consisted of about
3%–5% non-OT-I-CD8 T cells of the total CD8 T cells, into
Rag1/ mice bearing established human H460 tumors. There-
fore, only a few hundred T cells will react to human antigens
(Ags), which is similar to the number of tumor-reactive T cells
observed in human patients. In this model, the presence of
95% of OT-I cells was used to prevent rapid homeostasis
of extremely low numbers of CD8+ T cells in Rag1/ mice.
Antitumor T cell responses can be initiated for tumor regression
if proper activation is triggered by targeted treatment in this
tumormodel (Lee et al., 2009; Yang et al., 2013). Althoughmurine
IFNb cannot suppress human tumor cells in vitro, anti-EGFR
murine IFNb showed superior therapeutic effects compared to
anti-EGFR Ab alone in vivo (Figure 2C). To test whether anti-
EGFR-IFNb could control tumor metastasis, we injected B16-
EGFR intravenously into wild-type (WT) mice in order to mimic
tumor metastasis. We found that anti-EGFR-IFNb could controlCancer Cell 25, 37–48, January 13, 2014 ª2014 Elsevier Inc. 39
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Figure 2. IFNb Dramatically Enhances the Antitumor Effect of Antibody
(A) WT BALB/c mice (n = 5/group) were injected subcutaneously with 53 105 TUBO-EGFR cells and treated with 25 mg of anti-EGFR, anti-EGFR-IFNb, or control
antibody (Ab) on days 14, 18, and 22. The tumor growth was measured and compared twice weekly.
(B) WT B6 mice (n = 5/group) were injected subcutaneously with 73 105 B16-EGFR and treated with 25 mg of anti-EGFR, anti-EGFR-IFNb or control Ab on days
14, 18, and 22. The tumor growth was measured and compared twice weekly.
(C) Rag1/mice (n = 5/group) were injected subcutaneously with 33 106 H460 cells, and 23 106 ovalbumin-specific class I-restricted T cell (OT-I) LN cells were
adoptively transferred on day 13. Anti-EGFR-IFNb or control Ab (25 mg each) was administered on days 14, 18, and 22. The growth of the tumor was measured
and compared twice weekly.
(D) neuOT-I/OT-II-transgenic (neuOT-I/OT-II-Tg) female mice (n = 5/group) were injected subcutaneously with 1 3 106 NOP23 and treated with 25 mg of anti-neu,
anti-neu-IFNb or control Ab on days 14, 18, and 22. The tumor growth was measured and compared twice weekly.
(E) EGFR-Tgmice (n = 5/group) were injected subcutaneously with 53 105 B16-EGFR and treatedwith 25 mg of anti-EGFR, anti-EGFR-IFNb or control Ab on days
14, 18, and 22. The tumor growth was measured and compared twice weekly.
*p < 0.05 compared with control group. Mean ± SEM values are shown. Error bars indicate SEM. One representative experiment of a total of three is depicted.
See also Figure S2 and Table S1.
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longed the survival of the mice (data not shown).
Antitumor immunity mediated by anti-neu Ab treatment is
reduced in neu-Tg mice, as high neu expression (as self- and
tumor-associated Ags) in all mammary glands tolerizes host
immune cells during early life due to the nature of transgene
expression. The neuOT-I/OT-II-Tg mice model, in which onco-
genic rat neu is highly expressed in both mammary tumors and
normal mammary glands, is an important model for monitoring
the T cell response during spontaneous tumor development
and adoptive transfer cancer therapy (Wall et al., 2007; Yang
et al., 2009). NOP23 is one of the neu+ mammary tumor cell lines
generated from neuOT-I/OT-II-Tg mice (Yang et al., 2009). In this
study, we used NOP23 tumor-bearing neuOT-I/OT-II-Tg mice as
an neu-tolerized host model. Impressively, anti-neu-IFNb more
profoundly inhibited tumor growth than anti-neu Ab alone,
even in a tolerized model (Figure 2D). To test whether
anti-EGFR-IFNb could induce similar tumor regression in an
EGFR-tolerized host, we crossed EGFR-Tg mice in a mixed
background (Politi et al., 2006) to B6 background for ten gener-
ations to allow the growth of syngeneic B16-EGFR tumors. We40 Cancer Cell 25, 37–48, January 13, 2014 ª2014 Elsevier Inc.treated B16-EGFR-bearing EGFR-Tg mice with anti-EGFR-
IFNb. Consistent with anti-neu-IFNb, anti-EGFR-IFNb showed
a better antitumor effect than anti-EGFR alone (Figure 2E). We
also observed a similar increased antitumor effect by arming
another anti-EGFR Ab clone (cetuximab, C225) with IFNb
(data not shown). Collectively, these data suggest that Ab-IFNb
fusion protein therapy at low doses and for short durations is
superior to first-generation Ab therapy for controlling tumors,
even in Ab-resistant tumor models and in tolerized hosts
(Table S1).
Therapeutic Effect of Anti-EGFR-IFNb Fusion Protein
Depends on Adaptive Immunity
Because a previous study demonstrated that type I IFNs can
directly and potently induce apoptosis of tumor cells for tumor
regression (Xuan et al., 2010), we speculated that the anti-
EGFR-IFNb should show similar antitumor effects in Rag1/
mice compared with WT mice when the major mechanism
is the direct killing of tumor cells. However, anti-EGFR-IFNb
was surprisingly unable to inhibit tumor growth in these
immune-compromised Rag1/ mice (Figure 3A). Thus, these
A B
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Figure 3. Anti-EGFR-IFNb Can Induce Anti-
Tumor-Specific Cytotoxic T lymphocyte
Responses that Are Responsible for Tumor
Regression
(A) Wild-Type (WT) and Rag1/ B6 mice (n = 5/
group) were injected subcutaneously with 5 3 105
B16-EGFR-SIY cells and treated with 25 mg of anti-
EGFR-IFNborcontrolAbondays14,18, and22.The
tumor growth was monitored twice weekly. EGFR,
epidermal growth factor receptor; IFN, interferon.
(B) Seven days after last treatment, draining lymph
node (dLN) cells were collected and an IFNg
ELISPOT assay was performed with SIY peptide
restimulation.
(C) WT B6 mice (n = 5/group) were injected sub-
cutaneously with 5 3 105 B16-EGFR-SIY and
treated with 25 mg of anti-EGFR-IFNb or control
Ab on days 14, 18, and 22. A CD8-depleting
antibody (200 mg/mouse) was administered on the
same day as anti-EGFR-IFNb. The tumor growth
was measured and compared twice weekly.
(D) Seven days after the last treatment, dLN cells were collected and IFNg ELISPOT assay was performed with SIY peptide restimulation.
*p < 0.05 and **p < 0.01 compared with control group. Mean ± SEM values are shown. Error bars indicate SEM. One representative experiment of a total of three
is depicted. See also Figure S3.
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therapeutic effect requires adaptive immunity, not direct killing
of tumor cells.
CD8+ T lymphocytes are the major cell population involved in
controlling the growth of many tumors. To determine whether
they are also involved in the anti-EGFR-IFNb-mediated anti-
tumor effect, we tracked the antitumor T cell response during
the priming phase. We established a B16-EGFR-SIY tumor cell
line in which the SIY peptide (SIYRYYGL) was linked to EGFR
molecule. This SIY peptide serves as a surrogate marker that
can be specifically recognized by endogenous or 2C CD8+
T cells from Tg mice. After anti-EGFR-IFNb treatment, draining
lymph node (dLN) lymphocytes were isolated from tumor-
bearing mice and stimulated with SIY peptide, and IFNg produc-
tion was measured as an effector function readout of activated
T cells. As shown in Figure 3B, anti-EGFR-IFNb treatment
increased IFNg production from tumor Ag-specific T cells
compared with anti-EGFR treatment alone. To address whether
CD8+ cells are essential for the therapeutic effect of anti-EGFR-
IFNb, we administered a CD8-depleting Ab during anti-EGFR-
IFNb treatment in B16-EGFR-bearingWTB6mice andmeasured
tumor growth. CD8+ cell depletion eliminated the therapeutic
effect of anti-EGFR-IFNb (Figure 3C), suggesting that adaptive
immune responses are required for controlling tumor growth.
Consistent with this finding, we found that the T cell response
ex vivo dramatically decreased after anti-CD8 depletion (Fig-
ure 3D). The depletion of other cells, including natural killer
(NK) and B cells, did not affect the antitumor effect of anti-
EGFR-IFNb (Figure S3). Taken together, these data suggest
that anti-EGFR-IFNb treatment can increase T cell priming for
tumor regression.
Therapeutic Effect of Anti-EGFR-IFNb Requires IFNAR
Expression on Host Bone Marrow-Derived Cells
IFNAR is widely expressed on almost all cell types, thus both
normal and tumor cells are potential targets of anti-EGFR-
IFNb. The efficacy of anti-CD20-IFNa fusion protein has beenreported to require IFNAR expression on tumor cells (Xuan
et al., 2010). We therefore hypothesized that host cell-expressed
IFNAR may not be required for the therapeutic effect of anti-
EGFR-IFNb. To this end, we compared the antitumor effect in
tumor-bearing Ifnar1/ mice, which lack IFNAR expression on
host cells but not on tumor cells. To our surprise, the therapeutic
effect of anti-EGFR-IFNb was abolished in Ifnar1/ mice (Fig-
ure 4A). To study whether the IFNAR signaling on host cells is
associated with adaptive immune responses, we checked the
T cell responses after treatment and found that there was no
increased CTL response in Ifnar1/ mice (Figure 4B). These
results suggest that the therapeutic effect and related CTL
responses by anti-EGFR-IFNb require IFNAR-mediated activa-
tion in host cells, but not in tumor cells. Because all host tissues
express IFNAR, we constructed IFNAR bone marrow chimeric
(BMC) mice to further dissect whether IFNAR-expressing,
bone marrow-derived cells or stromal cells of the host are
required for the antitumor effect. We found that IFNAR ex-
pression on bone marrow-derived cells is required because
the antitumor effect of anti-EGFR-IFNb was dramatically
impaired in Ifnar1/BMC-reconstitutedmice (Figure 4C). These
data suggest that anti-EGFR-IFNb mediated its antitumor
effect, not by directly inhibiting tumor cell growth but by acti-
vating host bone marrow-derived cells to change the tumor
microenvironment.
Elevated Dendritic Cell Cross-Presentation Contributes
to the Antitumor Effect of Anti-EGFR-IFNb
Given that CD8+ cells are essential for the antitumor effect of
anti-EGFR-IFNb treatment, we further explored the mechanisms
underlying how anti-EGFR-IFNb enhance CTL responses. We
observed a dramatic increase in IFNg-producing CD8+ cells
after anti-EGFR-IFNb treatment, even without exogenous SIY
peptide stimulation, suggesting that cross-presentation of
APCs is increased (Figure 5A). Because cross-presentation
was proposed to be the dominant priming mechanism to
activate CTLs for antitumor immunity (Huang et al., 1994;Cancer Cell 25, 37–48, January 13, 2014 ª2014 Elsevier Inc. 41
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Figure 4. The Antitumor Effect of Anti-
EGFR-IFNb Requires IFNAR Expression on
Host Bone Marrow-Derived Cells
(A) WT and Ifnar1/ B6 mice (n = 5/group) were
injected subcutaneously with 5 3 105 B16-EGFR-
SIY cells and treated with 25 mg of anti-EGFR-IFNb
or control Ab on days 14, 18, and 22. Tumor
growth was monitored twice weekly.
(B) Seven days after the last treatment, draining
lymph node (dLN) and spleen cells were collected
and IFNg produced in supernatant was detected
by cytometric bead array assay.
(C)Thirtydaysafter indicatedbonemarrowchimera
reconstitution, mice were injected subcutaneously
with 73 105 B16-EGFR-SIY cells and treated with
25mgof anti-EGFR-IFNbor control immunoglobulin
three times. Tumor growth was measured and
compared twice weekly.
*p < 0.05 compared with control group. Mean ±
SEM values are shown. Error bars indicate
SEM. One of two representative experiments is
depicted.
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ing by fusion protein might be essential to restore dendritic cell
(DC) function to reactivate CTLs inside tumors and dLNs. To
address the possibility that anti-EGFR-IFNb could increase the
cross-presentation of APCs, we used an Ag-specific system to
track the priming and activation of tumor Ag-specific T cells.
DCs from the dLNs of anti-EGFR-IFNb-treated B16-EGFR-SIY-
bearing mice were assessed for their ability to enhance the
specific antitumor CTL response by incubating them with
SIY-reactive 2C T cells in an ex vivo assay. Indeed, DCs from
anti-EGFR-IFNb-treated mice induced more IFNg production
from 2C T cells (33 times) compared to anti-EGFR treatment,
evenwithout restimulationby exogenousSIYpeptide (Figure 5B).
Cumulatively, the data suggest that anti-EGFR-IFNb-activated
DCs enhance CD8+ T cell activation through an increased
cross-priming function. Furthermore, these results indicate that
the IFNb component of the fusion protein is responsible for
activating the DC cross-presentation pathway, as anti-EGFR
Ab alone did not induce strong DC activation.
Additionally, exogenous antigenic peptide (SIY) was added to
the culture to illicit an increased SIY-specific 2C T cell response
for better analysis of the overall direct priming function of
DCs. DCs from the anti-EGFR-IFNb-treated mice induced
approximately two times more IFNg production from the 2C
T cells than anti-EGFR Ab treatment alone upon exogenous
SIY peptide restimulation (Figure 5B). These results suggest
that DCs from the dLNs of anti-EGFR-IFNb-treated hosts are
likely to be more activated than DCs from mice treated with
anti-EGFR Ab alone. Indeed, these DCs have high expression
of activation markers, including CD86, as assessed by flow
cytometry (Figure 5C). To further discern whether anti-EGFR-
IFNb-induced DC activation is responsible for the enhanced
T cell activation, tumor-bearing CD11c-diphtheria toxin recep-
tor (CD11c-DTR) BMC mice were treated with diphtheria
toxin to deplete DCs during anti-EGFR-IFNb treatment. We
found that the anti-EGFR-IFNb-mediated therapeutic effect
is impaired when DCs are not present (Figure 5D). Taken42 Cancer Cell 25, 37–48, January 13, 2014 ª2014 Elsevier Inc.together, these data suggest that improved CD8+ CTL priming
and function by increased DC cross-presentation might be the
major mechanism underlying the therapeutic effect of anti-
EGFR-IFNb.
Anti-EGFR-IFNb Directly Targets DCs to Reverse
the Tolerized Tumor Microenvironment
Our data reveal that increased cross-priming is important for
the improved antitumor effect of anti-EGFR-IFNb treatment.
However, the IFNAR-expressing cells directly responsible for
the therapeutic effect of anti-EGFR-IFNb need to be identified.
To address this issue, Ifnar1flox/flox mice were bred to various
Cre-Tg mice. When IFNAR was selectively absent in CD11c+
cells in CD11c-Cre+Ifnar1flox/flox mice, the antitumor effect of
anti-EGFR-IFNb disappeared (Figure 6A), suggesting that direct
DC activation by anti-EGFR-IFNb may be the major contributor
to its therapeutic effect. When IFNAR was selectively absent in
T cells in CD4-Cre+Ifnar1flox/flox mice, the antitumor effect of
anti-EGFR-IFNb was slightly impaired (Figure 6B), suggesting
that direct targeting of IFNAR on T cells may further activate
T cells for an improved antitumor effect. To further test this
idea, we evaluated the effect of anti-EGFR-IFNb stimulation in
both DC and T cell activation in an in vitro assay. Indeed, we
found that anti-EGFR-IFNb increased the activation of both
DCs and T cells (Figure S5). These data collectively suggest
that direct activation of IFNAR-expressing DCs plays a major
role in the anti-EGFR-IFNb-mediated therapeutic effect, which
can be further enhanced by engaging IFNARs expressed on
T cells.
Antagonizing Anti-EGFR-IFNb-Induced PD-L1
Expression Achieves Tumor-free Outcome
Although anti-EGFR-IFNb fusion achieved a more effective
antitumor effect than anti-EGFR Ab alone, residual tumor
eventually relapsed. We wondered whether anti-EGFR-IFNb
treatment might induce inhibitory molecule expression on
tumor cells to prevent tissue-damaging immune responses,
C D
A B Figure 5. Anti-EGFR-IFNb Restores the
Cross-Presentation Ability of DCs
(A) WT B6 mice (n = 5/group) were injected sub-
cutaneously with 53 105 B16-EGFR-SIY cells and
treated with 25 mg of anti-EGFR-IFNb or control Ab
on days 14 and 18. Seven days after the last
treatment, draining lymph node (dLN) cells were
collected and an interferon-g (IFNg) ELISPOT
assay was performed without SIY peptide restim-
ulation. EGFR, epidermal growth factor receptor.
(B) WT B6 mice (n = 5/group) were injected sub-
cutaneously with 53 105 B16-EGFR-SIY cells and
treated with 25 mg of anti-EGFR-IFNb or control
Ab on days 14 and 17. Four days after the last
treatment, dendritic cells (DCs) from dLNs were
purified by CD11c+ selection and incubated with
purified naive 2C T cells with or without SIY pep-
tide restimulation. IFNg production was measured
2 days later.
(C) DC activation markers were measured by flow
cytometry.
(D) About 40 days after the indicated bone marrow chimera reconstitution, mice were injected subcutaneously with 5 3 105 B16-EGFR-SIY cells and treated
with 25 mg of anti-EGFR-IFNb or control immunoglobulin on days 14, 18, and 22. Diphtheria toxin or PBS was administrated on the same day as treatment. Tumor
growth was measured and compared twice weekly.
*p < 0.05 and **p < 0.01 compared with control group. Mean ± SEM values are shown. Error bars indicate SEM. One representative experiment of two or three
is depicted. See also Figure S4.
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IFNg is known to be the major inducer of PD-L1 on tumor cells
(Blank et al., 2004), it raises the possibility that type I IFNs have
a similar effect. We accordingly evaluated PD-L1 expression
after anti-EGFR-IFNb treatment and clearly observed increased
PD-L1 expression on tumor cells, both in vivo and in vitro (Fig-
ures 7A and 7B). The data confirm that type I IFNs could induce
the expression of this inhibitory molecule directly. To test
whether blocking PD-L1 expression could potentiate IFN-
mediated tumor rejection, we next combined anti-PD-L1 with
anti-EGFR-IFNb treatment and observed that anti-PD-L1
blockade further enhanced the long-term efficacy of anti-
EGFR-IFNb; indeed, mice remained tumor-free for at least
60 days after treatment (Figure 7C). To test whether such treat-
ment might have a prolonged protective effect in preventing
the growth of dormant residual cancer, mice without detectable
tumors were rechallenged with a lethal tumor dose. Impres-
sively, all of them were completely resistant to tumor rechal-
lenge (data not shown). Moreover, blocking the PD-L1 pathway
by anti-PD-L1 treatment further enhanced the specific anti-
tumor T cell response (Figure 7D). To test whether IFN-induced
PD-L1 is a dominant mechanism for immune evasion, we
tested whether blockade of two major inhibitory pathways on
T cells, CTLA-4 and B- and T-lymphocyte attenuator (BTLA),
could act synergistically with anti-EGFR-IFNb treatment. In
contrast to anti-PD-L1 Ab, we did not observe a similar syner-
gistic effect when we combined anti-EGFR-IFNb with anti-
CTLA-4 or anti-BTLA Ab (Figure S6). Collectively, our data
indicate that antagonizing anti-EGFR-IFNb-induced PD-L1
expression can maximize the antitumor effect of anti-EGFR-
IFNb and bring about an impressive tumor-free outcome,
even for Ab-resistant tumors. This combination-based strategy
will likely increase the overall response and cure rates of Ab-
resistant hosts, even in hosts that initially fail to respond to
anti-PD-1 or anti-PD-L1 Abs (Figure 8).DISCUSSION
A first generation of Abs to oncogenic receptors has been
increasingly used, but intrinsic and extrinsic resistance have
become major clinical challenges. In our present study, we
have revealed that type I IFNs play an essential and sufficient
role to bridge innate and adaptive antitumor immune responses
during Ab-based antitumor therapy. We have developed Ab-
IFNb as a representative, clinically relevant next generation of
Ab-based therapy that is superior to first-generation Ab therapy,
even in Ab-resistant tumor cells. Our study demonstrates the
following essential and sufficient role of type I IFNs for Ab-medi-
ated tumor control. (1) Type I IFN production is elevated after Ab-
based antitumor treatment. Blocking type I IFN signaling impairs
Ab-mediated tumor regression. (2) Targeted delivery of IFNb in-
side the tumor site by Ab-IFNb fusion protein greatly amplifies
the therapeutic effect of Abs. (3) Such antitumor effects depend
on DCs and CTLs. (4) Ab-IFNb increases DC cross-presentation
and antitumor CTLs by directly targeting IFNAR on DCs, but not
on tumor cells or T cells (Figure 8).
Most current strategies to improve the therapeutic effect of
Abs from a tumor-intrinsic angle focus on how to increase
tumor cell cytotoxicity by Ab and cytotoxic drug conjugates
(ADCs) (Fayad et al., 2013; Hurvitz et al., 2013; Krop et al.,
2012). Similar to the first generation of Abs, host resistance
can develop after prolonged ADC treatment. Indeed, many
patients still undergo relapse or develop metastasis despite
initial regression by the potent cytotoxic effects of ADCs. We
propose that this resistance develops because ADC relies on
directly killing specific tumor cells and thus cannot target all
tumor cells, causing some to be selected or to acquire the
ability to escape direct killing. The next generation of Ab-
based treatment we describe herein, however, can overcome
these types of resistance by revitalizing innate and adaptive
immune cells inside the tumor and generating specific T cellCancer Cell 25, 37–48, January 13, 2014 ª2014 Elsevier Inc. 43
AB
Figure 6. Dendritic Cells Are the Major Cell Type Directly Respond-
ing to Anti-EGFR-IFNb Treatment
(A) Ifnar1flox/flox and CD11c-Cre Ifnar1flox/flox mice (n = 5/group) were injected
subcutaneously with 5 3 105 B16-EGFR-SIY cells and treated with 25 mg
of anti-EGFR-IFNb or control Ab on days 14, 18, and 22. Tumor growth
was measured and compared twice weekly.
(B) Ifnar1flox/flox and CD4-Cre Ifnar1flox/flox mice (n = 5/group) were injected
subcutaneously with 5 3 105 B16-EGFR-SIY cells and treated with 25 mg of
anti-EGFR-IFNb or control Ab on days 14, 18, and 22. Tumor growth was
measured and compared twice weekly.
*p < 0.05 and **p < 0.01 compared with control group. Mean ± SEM values
are shown. Error bars indicate SEM. One representative experiment of two
is depicted. See also Figure S5.
Cancer Cell
Targeting Tumor by Armed Antibody with Interferonresponses that target multiple shared tumor-mutated Ags.
Thus, use of this strategy might be able to eradicate residual
tumor cells that Abs cannot directly target. Our study further
supports the argument that improving the effectiveness of anti-
tumor effector and memory T cell responses is important for
preventing relapse.
Type I IFNs have multiple potential effects on tumor growth,
including inhibiting proliferation, inhibiting angiogenesis, acti-
vating innate cells, bridging innate and adaptive immunity, and
directly activating adaptive immune responses. The reported
role of type I IFNs on tumor cells and immune cells is complex
and sometimes controversial. In the pioneer study by Xuan
et al. (2010), use of anti-CD20-IFNa clearly showed that type I
IFNs can have direct cytotoxic effects in lymphoma. Indeed,
lymphomas, including human lymphoma, are very sensitive to
type I IFN-mediated direct killing, not only in vitro but also in vivo.
Unexpectedly, we have shown that our Ab-IFNb can control
various carcinomas by the following different modes of action.
(1) Rag1/ mice bearing carcinomas failed to respond to
Ab-IFNb, suggesting the major role of adaptive immune cells.
(2) CD8-depleted mice showed early relapse, suggesting an
essential role of CTLs. (3) IFNAR+ carcinomas in Ifnar1/ mice
failed to respond to Ab-IFNb, suggesting that host IFNAR44 Cancer Cell 25, 37–48, January 13, 2014 ª2014 Elsevier Inc.signaling is essential. (4) We have further pinpointed that
IFNARs on DCs is essential for tumor regression. Since most
carcinoma cell lines are less sensitive to type I IFNs compared
with lymphoma cells, Ab-IFNb cannot kill them directly. There-
fore, the two studies, ours and that of Xuan et al., are com-
plementary and cover two different modes of action for
IFN-mediated tumor regression, depending on the sensitivity of
the targeted tumor to type I IFNs.
Endogenous type I IFNs have been shown to be required for
rejection of highly immunogenic tumor cells, which cannot
grow in WT mice (Diamond et al., 2011; Fuertes et al., 2011).
Those two studies also showed that type I IFNs are required
for only the first 6 days after tumor inoculation before the tumor
is established. Once the tumor is established after the first
6 days, the role of endogenous type I IFNs is diminished.
Complementarily, our study shows that endogenous type I
IFNs can still regain their essential role after blockade of
oncogenic addiction on established tumors that subsequently
triggers innate and adaptive immune responses. It is worthwhile
to mention that the therapeutic effect of Ab-IFNb in our study
was dependent on DCs, but not on CD8a+ DCs as shown in
Diamond et al.’s study (Diamond et al., 2011), because our
Ab-IFNb was effective in Batf3/ mice (Figure S4), which
might imply different mechanisms of enhancing the efficacy of
Ab-based therapeutics.
It is currently unclear whether the more effective strategy to
reactivate the antitumor T cell response within the tumor is to
target the activation of T cells or APCs. We recently observed
that, though single-chain variable fragments (neu)-IL-2 and -IL-
15 could expand T cells, even inside tumor tissues, these
T cells then failed to suppress tumor growth (data not shown).
Thus, directly targeting T cells without increasing APC function
may not initiate tumor-specific immune responses and instead
may nonselectively amplify all preexisting T cell responses.
Investigators in recent clinical trials who tested Abs that block
coinhibitory signals in T cells (CTLA-4, PD-1, and PD-L1) have
demonstrated that reversing T cell suppression is important
for effective cancer immunotherapy, as it impressively controlled
tumor growth in 15%–25% of cancer patients who failed to
respond to conventional treatment (Brahmer et al., 2012;
Sharma et al., 2011; Topalian et al., 2012; Weber, 2007). How-
ever, because these anti-inhibitory receptor Abs target all
T cells within the body rather than targeting T cells within tumor
tissues directly, they may cause unwanted tissue damage
or even autoimmune disease. Our current study demonstrates
that selective combination of Ab-IFNb and anti-PD-L1 can
have a synergistic effect on tumor regression, raising interest
in developing other combination therapies in the future.
Cross-presentation is the dominant priming mechanism to
activate CTL responses in antitumor immunity (Huang et al.,
1994; Kurts et al., 2010). Because DCs are the most important
APCs for cross-presentation (Steinman, 2012), targeting DCs
with Ab-IFNb confers several advantages. First, Ab-IFNb does
not directly kill tumor cells, which reduces side effects from
Ab-IFNb targeting normal cells outside tumor tissues. If DCs
in normal tissues do happen to become activated by this
immunotherapy, they cannot activate Ag-specific T cells due to
the lack of mutated neoantigens and preexisting Ag-specific
T cells. Second, Ab-IFNb mobilizes DCs to present a variety of
A B
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Figure 7. Antagonizing PD-L1 Expression
Induced by Anti-EGFR-IFNb Achieves
Tumor-free Outcome
(A) WT B6mice were injected subcutaneously with
5 3 105 B16-EGFR-SIY cells and treated with
25 mg of anti-EGFR-IFNb or control Ab on day 14.
Two days later, tumor cells were collected and
programmed cell death ligand 1 (PD-L1) expres-
sion was analyzed by flow cytometry. Red line
indicates control immunoglobulin (Ig)-treated
group, and blue line indicates anti-EGFR-IFNb-
treated group.
(B)B16-EGFR-SIYcells and treatedwith0.02mg/ml
of anti-EGFR-IFNb during in vitro cell culture. One
day later, tumor cells were collected and PD-L1
expression was analyzed by flow cytometry. Red
line indicates control Ig-stimulated cells and blue
line indicates anti-EGFR-IFNb-stimulated cells.
(C) WT B6 mice (n = 5/group) were injected
subcutaneously with 5 3 105 B16-EGFR-SIY cells
and treated with 25 mg of anti-EGFR-IFNb or
control Ab on days 14 and 18. A PD-L1-blocking
Ab (400 mg/mouse) was administered on the
same day as anti-EGFR-IFNb. Tumor growth was
measured and compared twice weekly.
(D) Fourteen days after the last treatment, sple-
nocytes were collected and an IFNg ELISPOT
assay was performed.
*p < 0.05 compared with control group. Mean ±
SEM values are shown. Error bars indicate SEM.
One representative experiment of three is de-
picted. See also Figure S6.
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multiple mutated neo-tumor Ags from all tumor cells, even those
not originally targeted by Ab therapy. This will ultimately help
prevent the appearance of resistant clones. Third, Ab-IFNb
therapy is a rather short-term and low-dose treatment, unlike
the prolonged high-dose treatment with Abs alone, and should
have lower toxicity than Ab-cytotoxic drug conjugates.
Overall, this study has several important implications for the
cancer immunotherapy field. First, it establishes a way to create
the next generation of Ab-based treatment, such as the Ab-IFNb
fusion protein, which elicits the adaptive arm of the immune
response to deal more effectively with Ab resistance and
relapse. Enhancing the CTL response can then in turn kill more
tumor cells to create a positive feedback loop. Second, our study
provides strong evidence that type I IFNs, which link innate and
adaptive antitumor immunity, are key players in Ab-mediated
tumor regression and therefore provide an important target
for cancer immunotherapy. Third, this study reveals that DCs
are the major tolerized cell type in tumors, implying that they
play a major role in determining the immunosuppressive tumor
microenvironment. Therefore, targeting DCs will be another
important strategy to improve the efficacy of cancer immu-
notherapy. Fourth, we found that blocking inhibitory PD-L1 upre-
gulated by Ab-IFNb treatment further enhanced the antitumor
effect, which puts forth the concept that antagonizing immuno-
therapy-induced adaptive resistance will maximize the thera-
peutic effect of immune therapy and could guide future clinical
treatment. Collectively, the strategies used in this study openup several avenues for optimizing targeted immune therapy
that may have great impact in antitumor drug discovery and
clinical cancer therapy.EXPERIMENTAL PROCEDURES
Mice
C57BL/6J and BALB/c mice were purchased from Harlan. Rag1/, 2C CD8+
T cell receptor (TCR)-Tg, CD11c-DTR-Tg, Batf3/, CD11c-Cre, and CD4-
Cre-Tg mice were purchased from The Jackson Laboratory. Ifnar1/ mice
were kindly provided by Dr. Anita Chong of the University of Chicago.
Ifnar1flox/flox mice were kindly provided by Dr. Ulrich Kalinke of the Institute
for Experimental Infection Research, Hanover, Germany (Kamphuis et al.,
2006). neuOT-I/OT-II-Tg mice in a B6 background were kindly provided by
Dr. Brad H. Nelson of the Trev & Joyce Deeley Research Centre, Victoria,
BC, Canada (Wall, et al., 2007). Tet-on-EGFR-Tg mice were kindly provided
by Harold Varmus (National Cancer Institute) in 2009 and crossed to a B6
background up to ten generations (Politi et al., 2006). All mice were maintained
under specific pathogen-free conditions. Animal care and use were carried out
in accordance with institutional and National Institutes of Health protocols
and guidelines, and all studies were approved by the Animal Care and Use
Committee of the University of Chicago.
Cell Lines and Reagents
H460 was purchased from the American Type Culture Collection (ATCC).
TUBO cells were cloned from a spontaneous mammary tumor in a BALB/c
neu-Tg mouse (Rovero et al., 2000). TUBO-EGFR was selected after transfec-
tion of pSEB-EGFR (L858R) plasmid with 2 mg/ml Blasticidin (InvivoGen).
B16-EGFR and B16-EGFR-SIY were selected for a single clone after being
transduced by lentivirus expressing human EGFR (L858R) or EGFR (L858R)-
SIY. NOP23 was cloned from a spontaneous mammary tumor in aCancer Cell 25, 37–48, January 13, 2014 ª2014 Elsevier Inc. 45
Figure 8. Proposed Model of How Type I IFNs Link Innate and
Adaptive Antitumor Immunity
Damage-associated molecular pattern peptides released from Ab-sensitive
tumors, but not from Ab-resistant tumors, after Ab therapy will induce type I
interferon (IFN) production. Ab-IFN mimics in situ type I IFN production in
Ab-resistant tumors. Type I IFNs simultaneously increase dendritic cell (DC)
cross-presentation for better cytotoxic T lymphocyte responses, directly
activate T cells, and induce programmed cell death ligand 1 (PD-L1) expres-
sion to weaken antitumor immunity. Ab-IFN combined with PD-L1 blockade
maximizes the antitumor immune responses.
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Targeting Tumor by Armed Antibody with InterferonB6-neuOT-I/OT-II-Tg mouse kindly provided by Dr. Brad H. Nelson of the Trev &
Joyce Deeley Research Centre. H460, TUBO, and B16 and its derivatives were
cultured in 5% CO2 and maintained in vitro in Dulbecco’s modified Eagle’s
medium supplemented with 10% heat-inactivated fetal bovine serum
(Sigma-Aldrich), 2 mmol/l L-glutamine, 0.1 mmol/l Minimum Essential Medium
nonessential amino acids, 100 U/ml penicillin, and 100 mg/ml streptomycin.
The anti-EGFRmonoclonal Ab (mAb) cetuximab was purchased from ImClone
Systems. Anti-CD8 (YTS 169.4.2), anti-NK1.1 (PK136), and anti-neu (7.16.4)
Abs were produced in-house. Anti-PD-L1 (10F.9G2) and anti-Ly-6G (1A8)
Abs were purchased from Bio X Cell. Anti-CD20 (5D2) Ab was kindly provided
by Ouyang Wenjun (Genentech). Anti-IFNAR (MAR-5A3) Ab was kindly pro-
vided by Dr. Robert Schreiber (Washington University in St. Louis). Adenovirus
expressing murine IFNb was produced as previously described (Burnette
et al., 2011).
Production of Ab-IFNb Fusion Protein
The V region of anti-EGFR was cloned from an anti-EGFR (LA22) hybridoma
(ATCC). The V region of heavy chain and light chain were cloned into AbVec-
immunoglobulin G1 and AbVec-k, respectively (Smith et al., 2009). Next,
mouse IFNbwas inserted into the C terminal of heavy chain as a fusion protein
with an SGGGGSGGGGSGGGGSGGGG linker. The whole heavy chain with
IFNb and the light chain were cloned to pEE6.4 and pEE12.4 (Lonza), respec-
tively. Next, both vectors were digested by NotI and BamHI restriction en-
zymes. The complete human cytomegalovirus major immediate-early heavy
chain/simian virus 40 transcription unit form-digested pEE6.4 plasmid was
ligated into the large NotI-BamHI fragment from the digested pEE12.4 plasmid
containing the light-chain expression cassette. The plasmid containing both
heavy and light chains was transfected into Chinese hamster ovary cells,
and stable clones were established according to the manufacturer’s manual
(Lonza). The fusion protein anti-EGFR-IFNb was purified by using a protein
A column according to the manufacturer’s manual (Repligen). Anti-neu-IFNb
was produced in the same way, except that the cDNA of the V region was
from anti-neu 7.16.4 hybridoma cells.46 Cancer Cell 25, 37–48, January 13, 2014 ª2014 Elsevier Inc.Tumor Growth and Treatments
Approximately 6 3 105 TUBO, TUBO-EGFR, B16-EGFR, B16-EGFR-SIY,
or NOP23 cells were injected subcutaneously on the right flank into 6- to
12-week-old mice. Tumor volumes were measured along three orthogonal
axes (a, b, and c) and calculated as tumor volume = (a 3 b 3 c)/2. After the
tumor was established (14 days), mice were treated with three intratumoral
injections of 25 mg of anti-EGFR-IFNb or control Ab every 4 days. For CD8
depletion experiments, 200 mg of anti-CD8 Ab was injected intraperitoneally
at the same time as the anti-EGFR-IFNb treatment. Approximately 3 3 106
H460 cells were injected subcutaneously on the right flank into 6- to
12-week-old Rag1/ mice. After the tumor was established (13 days),
2 3 106 LN cells from OT-I TCR-Tg mice were adoptively transferred to mice
by intravenous injection. One day later, mice were treated with three intra-
tumoral injections of 25 mg of anti-EGFR-IFNb or control Ab on days 14, 18,
and 22 after tumor inoculation.
Type I IFN mRNA Expression after Antibody Treatment
Approximately 63 105 TUBO, TUBO-EGFR, or B16-EGFR cells were injected
subcutaneously into the right flank of 6- to 12-week-old mice. Mice were
treated with 100 mg of anti-neu, anti-EGFR, or control Ab on day 14 after tumor
inoculation. Four days later, the tumor was digested with 1 mg/ml collagenase
VIII (Sigma-Aldrich) and 200 mg/ml DNaseI (Sigma-Aldrich) at 37C for 30 min.
Live CD45+ and CD45 cell population were sorted with the BD FACSAria II
cell sorter (BD Biosciences). Total RNA was isolated by using the RNeasy
Mini Kit (QIAGEN) and reverse-transcribed to cDNA with the Sensiscript
RT Kit (QIAGEN). The expression level of type I IFN mRNA was analyzed by
quantitative real-time PCR. The following primers were used for the assay.
Murine IFNa5: forward, 50-ATGAAGTCCATCAGCAGCTC-30; reverse,
50-AGGGGCTGTGTTTCTTCTCT-30
b-actin: forward, 50-ACACCCGCCACCAGTTCGC-30, reverse, 50-ATGG
GGTACTTCAGGGTCAGGATA-30
Measurement of IFNg-Secreting T Cells by Enzyme-Linked
Immunosorbent Spot Assay or Cytometric Bead Array Assay
SIY peptide-reactive T cells weremeasured by enzyme-linked immunosorbent
spot (ELISPOT) assay. Spleen or LN cells were resuspended in RPMI 1640
medium supplemented with 10% fetal calf serum, 2 mmol/l L-glutamine,
100 U/ml penicillin, and 100 mg/ml streptomycin. A total of 1 to 43 105 spleen
or LN cells were used for the assay. SIY peptide was added at a concentration
of 5 mg/ml. After 48 hr of incubation, IFNg production was determined with
an IFNg ELISPOT assay kit according to the manufacturer’s manual (BD Bio-
sciences) or by cytometric bead array assay (BD Biosciences). The visualized
cytokine spots were enumerated with the ImmunoSpot Analyzer (CTL).
Ex Vivo Dendritic Cell Cross-Presentation Assay
B16-EGFR-SIY-bearing mice were treated with 25 mg of anti-EGFR, or anti-
EGFR-IFNb intratumoral injection on days 14 and 17. Four days later, dLN cells
were digested with 1 mg/ml collagenase VIII (Sigma-Aldrich) and 200 mg/ml
DNaseI (Sigma-Aldrich) at 37C for 15 min. DCs were purified by EasySep
Mouse CD11c Positive Selection Kit (STEMCELL Technologies). Approxi-
mately 1 3 105 DCs were mixed together with purified 2 3 105 2C T cells
with or without 5 mg/ml SIY peptide to restimulate the T cells. Two days later,
the supernatants were collected and IFNg was measured by cytometric bead
array assay (BD Biosciences).
Generation of Bone Marrow Chimeras
WTmice were lethally irradiated with a single dose of 1,000 rads. The next day,
irradiated mice were adoptively transferred with 2 to 3 3 106 WT, Ifnar1/,
or CD11c-DTR-Tg donor bone marrow cells. Mice were maintained on
sulfamethoxazole and trimethoprim antibiotics (Bactrim) diluted in drinking
water for 4 weeks after reconstitution. Mice were injected with tumor cells
5 to 6 weeks after reconstitution.
Detection of Endotoxin in mAb and Fusion Protein Preparation
Endotoxin was measured by carrying out the limulus amebocyte lysate assay
(Cambrex). For all mAb preparations, the amount of endotoxin was determined
to be less than 0.2 endotoxin units (EU)/mg mAb.
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Single-cell suspensions of cells were incubated with anti-CD16/32 (anti-FcgIII/
II receptor, clone 2.4G2) for 10 min, then stained with conjugated Abs.
All fluorescently labeled mAbs were purchased from BioLegend or
eBioscience. Samples were analyzed on a FACSCanto flow cytometer
(BD Biosciences), and data were analyzed using FlowJo software (TreeStar).
Statistical Analysis
Mean values were compared using an unpaired Student’s two-tailed t test.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
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